IL302673A - Antibodies to opioid treatments - Google Patents
Antibodies to opioid treatmentsInfo
- Publication number
- IL302673A IL302673A IL302673A IL30267323A IL302673A IL 302673 A IL302673 A IL 302673A IL 302673 A IL302673 A IL 302673A IL 30267323 A IL30267323 A IL 30267323A IL 302673 A IL302673 A IL 302673A
- Authority
- IL
- Israel
- Prior art keywords
- seq
- antibody
- amino acid
- cdr
- sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Addiction (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063111699P | 2020-11-10 | 2020-11-10 | |
| PCT/US2021/058459 WO2022103700A1 (en) | 2020-11-10 | 2021-11-08 | Antibodies for opioid treatments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL302673A true IL302673A (en) | 2023-07-01 |
Family
ID=81601678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL302673A IL302673A (en) | 2020-11-10 | 2021-11-08 | Antibodies to opioid treatments |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230399418A1 (https=) |
| EP (1) | EP4244256A4 (https=) |
| JP (1) | JP7839789B2 (https=) |
| KR (1) | KR20230107301A (https=) |
| CN (1) | CN116745318A (https=) |
| AU (1) | AU2021377609A1 (https=) |
| CA (1) | CA3200523A1 (https=) |
| IL (1) | IL302673A (https=) |
| MX (1) | MX2023005032A (https=) |
| WO (1) | WO2022103700A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3267132A1 (en) * | 2022-09-09 | 2024-03-14 | Regents Of The University Of Minnesota | ANTIBODIES DIRECTED AGAINST FENTANYL AND ITS ANALOGUES AND THEIR METHODS OF USE |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200808822A (en) * | 2006-04-14 | 2008-02-16 | Amgen Inc | Erythropoietin receptor agonists |
| WO2013095091A2 (en) * | 2011-11-17 | 2013-06-27 | Aimm Therapeutics B.V. | Rsv g protein specific antibodies |
| AU2017345786B2 (en) * | 2016-10-21 | 2024-08-01 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
| WO2018140821A1 (en) * | 2017-01-26 | 2018-08-02 | Surrozen, Inc. | Tissue-specific wnt signal enhancing molecules and uses thereof |
| EP3880698A4 (en) * | 2018-11-14 | 2022-11-30 | RubrYc Therapeutics, Inc. | MANIPULATED CD25 POLYPEPTIDES AND USES THEREOF |
-
2021
- 2021-11-08 MX MX2023005032A patent/MX2023005032A/es unknown
- 2021-11-08 WO PCT/US2021/058459 patent/WO2022103700A1/en not_active Ceased
- 2021-11-08 CA CA3200523A patent/CA3200523A1/en active Pending
- 2021-11-08 AU AU2021377609A patent/AU2021377609A1/en active Pending
- 2021-11-08 KR KR1020237019397A patent/KR20230107301A/ko active Pending
- 2021-11-08 CN CN202180085311.0A patent/CN116745318A/zh active Pending
- 2021-11-08 US US18/250,230 patent/US20230399418A1/en active Pending
- 2021-11-08 EP EP21892637.6A patent/EP4244256A4/en active Pending
- 2021-11-08 JP JP2023527344A patent/JP7839789B2/ja active Active
- 2021-11-08 IL IL302673A patent/IL302673A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022103700A1 (en) | 2022-05-19 |
| MX2023005032A (es) | 2023-05-16 |
| CN116745318A (zh) | 2023-09-12 |
| KR20230107301A (ko) | 2023-07-14 |
| US20230399418A1 (en) | 2023-12-14 |
| EP4244256A4 (en) | 2024-12-25 |
| AU2021377609A1 (en) | 2023-06-08 |
| CA3200523A1 (en) | 2022-05-19 |
| JP2023548603A (ja) | 2023-11-17 |
| AU2021377609A9 (en) | 2024-09-26 |
| JP7839789B2 (ja) | 2026-04-02 |
| EP4244256A1 (en) | 2023-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6114326B2 (ja) | 組織因子経路阻害因子に対する抗体 | |
| IL273832A (en) | Anti-tau antibodies and uses thereof | |
| IL259832A (en) | Antibodies neutralize hiv | |
| IL255010B2 (en) | Methods of increasing strength and functionality with gdf8 inhibitors | |
| IL270894B (en) | Human antibodies to bet v 1 and methods of use thereof | |
| IL296214A (en) | Methods for treating atopic dermatitis by administering an il-4r antagonist | |
| IL295729A (en) | Bispecific engineered anti-2her proteins, preparations containing them and their uses | |
| WO2018067819A1 (en) | Compositions and methods for treatment of cancers | |
| KR20180084045A (ko) | 비형 간염 표면 항원에 대한 항체 및 그의 용도 | |
| JP2024540694A (ja) | 受容体型チロシンキナーゼＥｐｈＡ５に対する抗体－薬物コンジュゲート | |
| IL312237A (en) | Anti-CD37 antibody-drug conjugate | |
| IL323031A (en) | Use of anti-CEACAM5 immunoconjugates for the treatment of neuroendocrine tumors expressing CEACAM5 | |
| IL302673A (en) | Antibodies to opioid treatments | |
| IL318087A (en) | Antibody against human TRL7 | |
| Chen et al. | Development of fentanyl-specific monoclonal antibody (mAb) to antagonize the pharmacological effects of fentanyl | |
| CN114423454A (zh) | 抗类胰蛋白酶抗体的给药 | |
| IL302386A (en) | Methods of reducing tau in human subjects | |
| RU2841257C1 (ru) | Антитела для лечения опиоидной зависимости | |
| IL317192A (en) | Anti-CDH6 antibody-drug conjugate dosing regimen | |
| JP2024534004A (ja) | 抗トリプターゼ抗体のための投与量 | |
| JP5963233B2 (ja) | Ｈｔｌｖ−１関連脊髄症を治療または予防するための医薬および前記医薬を用いた抗体療法の治療効果の確認方法 | |
| IL295258A (en) | Anti-hepsin antibodies and uses thereof | |
| IL297485A (en) | Compounds and their pharmaceutical uses | |
| WO2024109709A1 (en) | Ph-dependent anti-egfr antibodies for treatment of solid tumors | |
| HK40067775A (en) | Dosing for anti-tryptase antibodies |